Semaglutide for PCOS & Insulin Resistance

Candidate profile

Premenopausal women with a confirmed diagnosis of polycystic ovary syndrome (Rotterdam criteria: at least 2 of 3 — oligo/anovulation, clinical or biochemical hyperandrogenism, polycystic ovarian morphology) who have concurrent metabolic dysfunction. Specifically: BMI above 27 kg/m2 with insulin resistance (elevated fasting insulin, HOMA-IR above 2.5, or impaired glucose tolerance), and/or prediabetes or type 2 diabetes.

Ideal candidates are those who have not achieved adequate metabolic improvement with lifestyle modification alone (diet, exercise, 3-6 months), or who have failed or are intolerant to metformin — the traditional first-line insulin sensitizer for PCOS.

Not appropriate for women actively trying to conceive (semaglutide should be discontinued at least 2 months before planned conception due to insufficient reproductive safety data). Not appropriate as a cosmetic weight loss tool in lean PCOS phenotypes without metabolic dysfunction.

Approach

Once-weekly subcutaneous semaglutide targets the metabolic core of PCOS — hyperinsulinemia driving ovarian androgen production — while simultaneously addressing the weight excess that worsens insulin resistance. The approach treats the upstream metabolic pathology rather than managing downstream symptoms (hirsutism, acne, menstrual irregularity) individually.

Protocol design

Primary peptide: Semaglutide, dose-titrated

Route: Subcutaneous (abdomen, thigh, or upper arm)

Frequency: Once weekly, same day each week

Dose titration:

• Weeks 1-4: 0.25 mg weekly (initiation dose, primarily for GI tolerability)
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly (assess response)
• Weeks 13+: 1.7-2.4 mg weekly if tolerated and additional benefit needed

Timing: Any time of day, with or without food. Consistency of day matters more than timing.

Duration: Minimum 6 months to assess full metabolic and hormonal response. Most practitioners plan for 12+ months, as PCOS is a chronic condition requiring sustained metabolic improvement.

Concurrent medications: Continue or initiate spironolactone (50-100 mg daily) for androgen-dependent symptoms (hirsutism, acne) if needed — semaglutide addresses the metabolic root but may take 3-6 months to meaningfully reduce androgen levels. Combined oral contraceptives can be continued for cycle regulation if not contraindicated.

Mechanism summary

PCOS pathophysiology centers on a vicious cycle: insulin resistance leads to compensatory hyperinsulinemia, which directly stimulates ovarian theca cells to produce excess androgens (testosterone, androstenedione) via upregulation of CYP17A1 (17alpha-hydroxylase/17,20-lyase). Excess androgens impair follicular development, causing anovulation, and promote visceral fat deposition, which worsens insulin resistance — completing the cycle.

Semaglutide interrupts this cycle at multiple points. As a GLP-1 receptor agonist, it enhances glucose-dependent insulin secretion from pancreatic beta cells (reducing the beta cell workload and postprandial glucose spikes), slows gastric emptying (reducing postprandial glucose excursions), and suppresses appetite through hypothalamic GLP-1 receptor activation (reducing caloric intake and promoting weight loss).

Weight loss of 5-10% of body weight — readily achievable with semaglutide — independently improves insulin sensitivity, reduces circulating insulin levels, and consequently decreases ovarian androgen production. Some clinical data suggests GLP-1 receptor agonists may also have direct ovarian effects, reducing androgen synthesis independent of weight and insulin changes, though this remains under investigation.

The downstream effects of reduced androgens include improved follicular development (potentially restoring ovulatory cycles), decreased hirsutism and acne (over months, as these are slow-responding endpoints), and improved metabolic markers (lower triglycerides, improved HDL, reduced inflammatory markers).

Expected timeline

Weeks 1-4 (0.25 mg): GI adaptation period. Nausea is common (reported in 15-20% of patients) but typically manageable and transient. Appetite suppression begins. Minimal metabolic changes at this dose — the primary goal is tolerability.

Weeks 5-12 (0.5-1.0 mg): Weight loss becomes clinically apparent (typically 2-4 kg by week 12). Fasting insulin begins to decline. Fasting glucose improves in those with prediabetes. Menstrual irregularity may persist — too early to expect hormonal normalization.

Months 3-6: Weight loss of 5-10% achievable. HOMA-IR improves significantly. Free testosterone levels begin to decline as hyperinsulinemia resolves. Some patients report spontaneous menstrual cycles returning. This is the earliest point at which hormonal endpoints should be formally reassessed.

Months 6-12: Maximum metabolic benefit. Total and free testosterone may normalize or significantly decrease. SHBG (sex hormone-binding globulin) increases as insulin levels drop (insulin suppresses hepatic SHBG production). Menstrual regularity improves in many patients. Hirsutism improvement is slow — terminal hair growth cycles last months, so visible changes take 6-12 months.

Monitoring

• Body weight and waist circumference — monthly
• Fasting glucose, fasting insulin, HbA1c — baseline, 3 months, 6 months, then every 6 months
• HOMA-IR — calculated from fasting glucose and insulin at each metabolic assessment
• Total testosterone, free testosterone, SHBG — baseline, 3 months, 6 months
• Lipid panel — baseline and every 6 months
• Menstrual diary — ongoing patient-reported tracking of cycle length and regularity
• Liver function (ALT) — baseline and at 3 months (rare reports of hepatic effects)
• GI symptom assessment — at each dose escalation to guide titration speed

Evidence assessment

Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), but not specifically for PCOS. Its use in PCOS is off-label, though supported by growing clinical evidence. Multiple randomized controlled trials have demonstrated that GLP-1 receptor agonists (including liraglutide and exenatide) improve body weight, insulin sensitivity, androgen profiles, and menstrual regularity in women with PCOS. Semaglutide-specific PCOS trials are ongoing, with preliminary data showing superior weight loss and metabolic improvement compared to metformin.

The evidence base for GLP-1 agonists in PCOS is stronger than for most peptide use cases — these are approved drugs being studied in a related but off-label indication, with biological rationale supported by understanding of PCOS pathophysiology. The main evidence gap is long-term reproductive outcomes (fertility, pregnancy rates) and whether metabolic benefits persist after discontinuation.